UPDATE: ENV-105 Extends Median PFS to 17.7 Months in mCRPC
We updated you about the positive results of carotuximab (ENV-105) in this previous post. Now phase 2 data suggest that ENV-105 combined with apalutamide may substantially delay progression in metastatic castration-resistant prostate cancer (mCRPC) compared with apalutamide alone. In the randomised study, median progression-free survival reached 17.7 months with ENV-105 plus apalutamide, compared with just […]
